Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients.

Sergio Siragusa, Francesco Passamonti, Ayalew Tefferi, Francisco Cervantes

Risultato della ricerca: Article

12 Citazioni (Scopus)

Abstract

Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF
Lingua originaleEnglish
pagine (da-a)140-143
Numero di pagine4
RivistaAmerican Journal of Hematology
Volume84
Stato di pubblicazionePublished - 2009

Fingerprint

Primary Myelofibrosis
Stem Cell Transplantation
Databases
Transplants
Survival
Morbidity
Drug Therapy
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cita questo

Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients. / Siragusa, Sergio; Passamonti, Francesco; Tefferi, Ayalew; Cervantes, Francisco.

In: American Journal of Hematology, Vol. 84, 2009, pag. 140-143.

Risultato della ricerca: Article

@article{7762c8a18d5c4285b5ffe600878f4faf,
title = "Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients.",
abstract = "Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87{\%} and 55{\%}, 95{\%} and 77{\%}, 71{\%} and 58{\%}, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF",
keywords = "myelofibrosis, survival",
author = "Sergio Siragusa and Francesco Passamonti and Ayalew Tefferi and Francisco Cervantes",
year = "2009",
language = "English",
volume = "84",
pages = "140--143",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients.

AU - Siragusa, Sergio

AU - Passamonti, Francesco

AU - Tefferi, Ayalew

AU - Cervantes, Francisco

PY - 2009

Y1 - 2009

N2 - Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF

AB - Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF

KW - myelofibrosis, survival

UR - http://hdl.handle.net/10447/47401

M3 - Article

VL - 84

SP - 140

EP - 143

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

ER -